The Ozempic Lawsuit focuses on claims that the diabetes and weight loss medication, Ozempic, has caused severe gastrointestinal issues, including gastroparesis (paralysis of the stomach), nausea, vomiting, and other serious side effects
Please see individual product pages for details
Renal function should be monitored in patients experiencing severe gastrointestinal adverse effects
GLP-1 medications are changing how people think about weight loss and how they actually lose weight, driving changes in views about obesity care among health systems and providers and affecting the broader US economy
Patients who continue semaglutide maintain their weight loss and continue to see additional benefits: sustained appetite reduction, improved metabolic markers, and lower cardiovascular risk
The best place to inject peptides is typically an area with enough fatty tissue to comfortably accommodate a subcutaneous injection